All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What’s new for the management of polycythemia vera?

During the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Heinz Gisslinger, Medical University of Vienna, Vienna, AT. We asked, What’s new for the management of polycythemia vera (PV)?

What’s new for the management of polycythemia vera?

Recent years have seen progress in the management of PV in the form of lowering hematocrit levels and using aspirin to prevent thromboembolic events. Gisslinger discusses when and how to use cytoreductive therapy based on available data on ropeginterferon compared with hydroxyurea in PV.

Share:

Related articles

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox